Tumores Gastrintestinais

M-A | Quimiorradioterapia seguida de vigilância ativa vs. esofagectomia padrão para câncer esofágico.

13 Mai, 2022 | 12:24h

Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-analysis – Annals of Surgery (link para o resumo – $ para o texto completo)

Diretriz | Dissecção endoscópica da submucosa para lesões gastrintestinais superficiais.

12 Mai, 2022 | 14:33h

Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2022 – Endoscopy

M-A | Comparação de sobrevida entre adultos com câncer retal submetidos a laparoscopia vs. cirurgia aberta.

12 Mai, 2022 | 14:27h

Comparison of Survival Among Adults With Rectal Cancer Who Have Undergone Laparoscopic vs Open Surgery: A Meta-analysis – JAMA Network Open

Comentário no Twitter

This meta-analysis of 12 RCTs found laparoscopic rectal cancer resection is associated with better long-term overall survival vs open surgery, suggesting it may be time for routine use of laparoscopic surgery for rectal cancer. https://t.co/jb7YAkHDWM

— JAMA Network Open (@JAMANetworkOpen) May 9, 2022

Estudo randomizado | Análise final de 3 vs. 6 meses de oxaliplatina adjuvante e terapia baseada em fluoropirimidina em pacientes com câncer de cólon estágio III.

12 Mai, 2022 | 14:26h

Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial – Journal of Clinical Oncology

Comentários no Twitter

In Asian (Japan) patients with stage III colon cancer, 3 months of CAPOX therapy is an appropriate adjuvant treatment option in patients with low-risk disease- ACHIEVE trialhttps://t.co/BzjepOoal8

— K Pavithran (@drkpavithran) May 6, 2022

Estratégias atuais e futuras para rastreamento de câncer colorretal.

12 Mai, 2022 | 14:20h

Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (se o acesso a este link for pago, tente este em PMC)

Estudo randomizado | Tislelizumabe vs. quimioterapia como tratamento de segunda linha para carcinoma esofágico de células escamosas avançado ou metastático.

4 Mai, 2022 | 13:37h

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study – Journal of Clinical Oncology

Comentário no Twitter

In the phase III RATIONALE-302 trial of tislelizumab vs chemotherapy as 2nd-line therapy for advanced-stage ESCC, mOS was 8.6 vs 6.3 months (HR 0.70; P=0.0001), rising to 10.3 vs 6.8 months for those with a PD-L1 tumour area positivity score >10%: https://t.co/CNxads2Kn2 #esocsm

— NatureRevClinOncol (@NatRevClinOncol) April 27, 2022

M-A | Definição de câncer esofagogástrico oligometastático e impacto do tratamento local direcionado à oligometástase.

4 Mai, 2022 | 13:32h

Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis – European Journal of Cancer

Tratamento clínico de câncer colorretal metastático na era da medicina de precisão.

3 Mai, 2022 | 16:03h

Clinical management of metastatic colorectal cancer in the era of precision medicine – CA: A Cancer Journal for Clinicians

Estudo randomizado | Preservação de órgão em pacientes com adenocarcinoma retal tratado com terapia neoadjuvante total.

3 Mai, 2022 | 15:48h

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy – Journal of Clinical Oncology

Abordagem baseada em evidências para o tratamento de tumores da junção esofagogástrica.

2 Mai, 2022 | 13:38h

Evidence-based approach to the treatment of esophagogastric junction tumors – World Journal of Clinical Oncology